Kiora Pharmaceuticals (NASDAQ: KPRX) announced the publication of its Phase 1 ABACUS-1 study results for KIO-301 in Nature Medicine. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE